News
GlobalData on MSN4d
EC approves AstraZeneca’s Imfinzi combo for NSCLCThe European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...
AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...
AstraZeneca (LSE:AZN) saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, ...
Zacks.com on MSN3d
AZN Gets EU Nod for Expanded Use of Two Separate Cancer DrugsThe European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label ...
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable non-small cell lung cancer (NSCLC) in adults. NSCLC is the most prevalent form ...
The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...
David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...
AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...
In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback